Beatriz Monteiro Fernandes1, Estêvão Scotti-Muzzi2, Márcio Gerhardt Soeiro-de-Souza2. 1. Department and Institute of Psychiatry, Hospital das Cllínicas, School of Medicine, University of São Paulo (IPq HC-FMUSP), Dr. Ovidio Pires de Campos s/n, São Paulo, 05403-010, Brazil. beatriz.fernandes@gmail.com. 2. Department and Institute of Psychiatry, Hospital das Cllínicas, School of Medicine, University of São Paulo (IPq HC-FMUSP), Dr. Ovidio Pires de Campos s/n, São Paulo, 05403-010, Brazil.
Abstract
OBJECTIVE: To conduct a systematic review and meta-analysis of the effects of antidepressant drug therapy (with or without physical exercise) on peripheral inflammatory markers in patients with major depressive disorder (MDD). METHODS: MEDLINE, PyscINFO, Embase, and Google Scholar databases were searched until May 2020. Randomized trials that measured at least one inflammatory biomarker and included adult outpatients with MDD under antidepressant drug therapy (any drug) with or without physical exercise (any modality) were eligible. Results were summarized using the standardized mean difference (SMD) with 95% confidence intervals (95% CI) under a random-effects model. The Cochrane risk of bias tool (2010) was used to evaluate the risk of bias in the included trials. RESULTS: Sixty-three trials were identified, encompassing data from 3482 patients, and 20 investigated biomarkers. Trials had biases across multiple domains, rising concerns primarily to selection bias/performance bias/detection bias/attrition bias. SMDs between pre- and post-results indicated a significant reduction in the levels of IL-2 (SMD, - 0.25; 95% CI, - 0.41 to - 0.09, P = 0.002), IL-6 (SMD, - 0.19; 95% CI, - 0.35 to - 0.025, P = 0.024), IL-10 (SMD, - 0.32; 95% CI, - 0.57 to - 0.07, P = 0.011), and serum cortisol (SMD, - 0.35; 95% CI, - 0.58 to - 0.12, P = 0.002). Evidence supporting the influence of physical exercise combined with antidepressant drugs on peripheral inflammatory markers in MDD is sparse and heterogeneous. CONCLUSION: There is some evidence that antidepressant drug therapy is associated with an overall positive reduction in inflammatory markers, but the evidence is heterogeneous. Further research linking how inflammatory biomarkers modulate physiology related to antidepressant response is required. TRIAL REGISTRATION: CRD42020220735.
OBJECTIVE: To conduct a systematic review and meta-analysis of the effects of antidepressant drug therapy (with or without physical exercise) on peripheral inflammatory markers in patients with major depressive disorder (MDD). METHODS: MEDLINE, PyscINFO, Embase, and Google Scholar databases were searched until May 2020. Randomized trials that measured at least one inflammatory biomarker and included adult outpatients with MDD under antidepressant drug therapy (any drug) with or without physical exercise (any modality) were eligible. Results were summarized using the standardized mean difference (SMD) with 95% confidence intervals (95% CI) under a random-effects model. The Cochrane risk of bias tool (2010) was used to evaluate the risk of bias in the included trials. RESULTS: Sixty-three trials were identified, encompassing data from 3482 patients, and 20 investigated biomarkers. Trials had biases across multiple domains, rising concerns primarily to selection bias/performance bias/detection bias/attrition bias. SMDs between pre- and post-results indicated a significant reduction in the levels of IL-2 (SMD, - 0.25; 95% CI, - 0.41 to - 0.09, P = 0.002), IL-6 (SMD, - 0.19; 95% CI, - 0.35 to - 0.025, P = 0.024), IL-10 (SMD, - 0.32; 95% CI, - 0.57 to - 0.07, P = 0.011), and serum cortisol (SMD, - 0.35; 95% CI, - 0.58 to - 0.12, P = 0.002). Evidence supporting the influence of physical exercise combined with antidepressant drugs on peripheral inflammatory markers in MDD is sparse and heterogeneous. CONCLUSION: There is some evidence that antidepressant drug therapy is associated with an overall positive reduction in inflammatory markers, but the evidence is heterogeneous. Further research linking how inflammatory biomarkers modulate physiology related to antidepressant response is required. TRIAL REGISTRATION: CRD42020220735.
Authors: Cristiano A Köhler; Thiago H Freitas; Brendon Stubbs; Michael Maes; Marco Solmi; Nicola Veronese; Nayanna Q de Andrade; Gerwyn Morris; Brisa S Fernandes; André R Brunoni; Nathan Herrmann; Charles L Raison; Brian J Miller; Krista L Lanctôt; André F Carvalho Journal: Mol Neurobiol Date: 2017-06-13 Impact factor: 5.590
Authors: Jia Jia Liu; Ya Bin Wei; Rebecca Strawbridge; Yanping Bao; Suhua Chang; Le Shi; Jianyu Que; Bharathi S Gadad; Madhukar H Trivedi; John R Kelsoe; Lin Lu Journal: Mol Psychiatry Date: 2019-08-19 Impact factor: 15.992
Authors: Michael Gleeson; Nicolette C Bishop; David J Stensel; Martin R Lindley; Sarabjit S Mastana; Myra A Nimmo Journal: Nat Rev Immunol Date: 2011-08-05 Impact factor: 53.106
Authors: Madhukar H Trivedi; Tracy L Greer; Timothy S Church; Thomas J Carmody; Bruce D Grannemann; Daniel I Galper; Andrea L Dunn; Conrad P Earnest; Prabha Sunderajan; Steven S Henley; Steven N Blair Journal: J Clin Psychiatry Date: 2011-05 Impact factor: 4.384
Authors: R Strawbridge; D Arnone; A Danese; A Papadopoulos; A Herane Vives; A J Cleare Journal: Eur Neuropsychopharmacol Date: 2015-06-20 Impact factor: 4.600